[全球临床试验中结核病疫苗开发的最新进展：综述]。

Q3 Medicine

中国血吸虫病防治杂志 Pub Date : 2024-03-29 DOI:10.16250/j.32.1374.2023102

F Zhou, Y Zhang, D Zhang

{"title":"[全球临床试验中结核病疫苗开发的最新进展：综述]。","authors":"F Zhou, Y Zhang, D Zhang","doi":"10.16250/j.32.1374.2023102","DOIUrl":null,"url":null,"abstract":"Tuberculosis (TB) remains one of the biggest infectious killers worldwide. Vaccine is the most satisfactory tool for prevention of TB; however, Bacillus Calmette-Guérin (BCG), the widely used vaccine in clinical for the prevention of TB, has limitations in protective effects. Development of novel TB vaccines is therefore of urgent need. Currently, there are 15 novel TB vaccine candidates in clinical trials, including live-attenuated vaccines, inactivated vaccines, subunit vaccines and viral-vectored vaccines, which open the door for the ultimate target of the End TB Strategy. This review summarizes the latest advances in the development of TB vaccines in global clinical trials, so as to provide insights into TB control.","PeriodicalId":38874,"journal":{"name":"中国血吸虫病防治杂志","volume":"36 2","pages":"201-206"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Latest advances in the development of tuberculosis vaccines in global clinical trials: a review].\",\"authors\":\"F Zhou, Y Zhang, D Zhang\",\"doi\":\"10.16250/j.32.1374.2023102\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Tuberculosis (TB) remains one of the biggest infectious killers worldwide. Vaccine is the most satisfactory tool for prevention of TB; however, Bacillus Calmette-Guérin (BCG), the widely used vaccine in clinical for the prevention of TB, has limitations in protective effects. Development of novel TB vaccines is therefore of urgent need. Currently, there are 15 novel TB vaccine candidates in clinical trials, including live-attenuated vaccines, inactivated vaccines, subunit vaccines and viral-vectored vaccines, which open the door for the ultimate target of the End TB Strategy. This review summarizes the latest advances in the development of TB vaccines in global clinical trials, so as to provide insights into TB control.\",\"PeriodicalId\":38874,\"journal\":{\"name\":\"中国血吸虫病防治杂志\",\"volume\":\"36 2\",\"pages\":\"201-206\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国血吸虫病防治杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.16250/j.32.1374.2023102\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国血吸虫病防治杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.16250/j.32.1374.2023102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

结核病（TB）仍然是全球最大的传染病杀手之一。疫苗是预防结核病最理想的工具；然而，卡介苗（Bacillus Calmette-Guérin，BCG）作为临床上广泛使用的预防结核病的疫苗，其保护效果存在局限性。因此，开发新型结核病疫苗迫在眉睫。目前，有 15 种新型结核病候选疫苗正在进行临床试验，包括减毒活疫苗、灭活疫苗、亚单位疫苗和病毒载体疫苗，这为终结结核病战略的最终目标打开了大门。本综述总结了全球临床试验中结核病疫苗开发的最新进展，以期为结核病控制提供启示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Latest advances in the development of tuberculosis vaccines in global clinical trials: a review].

Tuberculosis (TB) remains one of the biggest infectious killers worldwide. Vaccine is the most satisfactory tool for prevention of TB; however, Bacillus Calmette-Guérin (BCG), the widely used vaccine in clinical for the prevention of TB, has limitations in protective effects. Development of novel TB vaccines is therefore of urgent need. Currently, there are 15 novel TB vaccine candidates in clinical trials, including live-attenuated vaccines, inactivated vaccines, subunit vaccines and viral-vectored vaccines, which open the door for the ultimate target of the End TB Strategy. This review summarizes the latest advances in the development of TB vaccines in global clinical trials, so as to provide insights into TB control.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国血吸虫病防治杂志 Medicine-Medicine (all)

CiteScore

1.30

自引率

0.00%

发文量

7021

期刊介绍： Chinese Journal of Schistosomiasis Control (ISSN: 1005-6661, CN: 32-1374/R), founded in 1989, is a technical and scientific journal under the supervision of Jiangsu Provincial Health Commission and organised by Jiangsu Institute of Schistosomiasis Control. It is a scientific and technical journal under the supervision of Jiangsu Provincial Health Commission and sponsored by Jiangsu Institute of Schistosomiasis Prevention and Control. The journal carries out the policy of prevention-oriented, control-oriented, nationwide and grassroots, adheres to the tenet of scientific research service for the prevention and treatment of schistosomiasis and other parasitic diseases, and mainly publishes academic papers reflecting the latest achievements and dynamics of prevention and treatment of schistosomiasis and other parasitic diseases, scientific research and management, etc. The main columns are Guest Contributions, Experts‘ Commentary, Experts’ Perspectives, Experts' Forums, Theses, Prevention and Treatment Research, Experimental Research, The main columns include Guest Contributions, Expert Commentaries, Expert Perspectives, Expert Forums, Treatises, Prevention and Control Studies, Experimental Studies, Clinical Studies, Prevention and Control Experiences, Prevention and Control Management, Reviews, Case Reports, and Information, etc. The journal is a useful reference material for the professional and technical personnel of schistosomiasis and parasitic disease prevention and control research, management workers, and teachers and students of medical schools. 　　 The journal is now included in important domestic databases, such as Chinese Core List (8th edition), China Science Citation Database (Core Edition), China Science and Technology Core Journals (Statistical Source Journals), and is also included in MEDLINE/PubMed, Scopus, EBSCO, Chemical Abstract, Embase, Zoological Record, JSTChina, Ulrichsweb, Western Pacific Region Index Medicus, CABI and other international authoritative databases.